Published in Clin Gastroenterol Hepatol on February 07, 2008
Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions. Am J Public Health (2009) 1.57
Sharing genetic risk with next generation: mutation-positive parents' communication with their offspring in Lynch Syndrome. Fam Cancer (2011) 1.23
Colorectal cancer risk perception on the basis of genetic test results in individuals at risk for Lynch syndrome. J Clin Oncol (2009) 0.96
Colon cancer screening practices and disclosure after receipt of positive or inconclusive genetic test results for hereditary nonpolyposis colorectal cancer. Cancer (2009) 0.90
Ethical issues of predictive genetic testing for diabetes. J Diabetes Sci Technol (2009) 0.89
Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease. J Health Commun (2009) 0.87
Perceived ambiguity as a barrier to intentions to learn genome sequencing results. J Behav Med (2015) 0.87
Evaluating the utilization of educational materials in communicating about Lynch syndrome to at-risk relatives. Fam Cancer (2014) 0.85
The genetic basis of Lynch syndrome and its implications for clinical practice and risk management. Appl Clin Genet (2014) 0.84
Family perspectives in lynch syndrome becoming a family at risk, patterns of communication and influence on relations. Hered Cancer Clin Pract (2012) 0.84
Understanding patterns of health communication in families at risk for hereditary nonpolyposis colorectal cancer: examining the effect of conclusive versus indeterminate genetic test results. Health Commun (2011) 0.83
Health behaviors in patients and families with hereditary colorectal cancer. Clin Colon Rectal Surg (2012) 0.80
Disclosing Genetic Information to Family Members About Inherited Cardiac Arrhythmias: An Obligation or a Choice? J Genet Couns (2014) 0.79
Genetic counseling and cascade genetic testing in Lynch syndrome. Fam Cancer (2016) 0.78
Prevalence and correlates of receiving and sharing high-penetrance cancer genetic test results: findings from the Health Information National Trends Survey. Public Health Genomics (2015) 0.78
Information-seeking and sharing behavior following genomic testing for diabetes risk. J Genet Couns (2014) 0.78
Controversies in communication of genetic screening results for cancer: a report from the American Society of Preventive Oncology's Screening Special Interest Group (ASPO's 33rd Annual Meeting, March 8 to 10, 2009, Tampa, Florida). Cancer Epidemiol Biomarkers Prev (2010) 0.78
Screening adherence and cancer risk perceptions in colorectal cancer survivors with Lynch-like syndrome. Clin Genet (2015) 0.78
Attitudes toward childbearing and prenatal testing in individuals undergoing genetic testing for Lynch syndrome. Fam Cancer (2011) 0.77
Genetic testing for Lynch syndrome: family communication and motivation. Fam Cancer (2016) 0.75
Hereditary colorectal cancer registries in Canada: report from the Colorectal Cancer Association of Canada consensus meeting; Montreal, Quebec; October 28, 2011. Curr Oncol (2013) 0.75
A Family-Centered Model for Sharing Genetic Risk. J Law Med Ethics (2015) 0.75
Effect of Disclosing Genetic Risk for Coronary Heart Disease on Information Seeking and Sharing: The MI-GENES Study (Myocardial Infarction Genes). Circ Cardiovasc Genet (2017) 0.75
Patient experiences with pharmacogenetic testing in a primary care setting. Pharmacogenomics (2016) 0.75
Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives. Fam Cancer (2017) 0.75
Uptake of genetic testing by the children of Lynch syndrome variant carriers across three generations. Eur J Hum Genet (2017) 0.75
A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst (1997) 5.68
The "duty to warn" a patient's family members about hereditary disease risks. JAMA (2004) 4.13
AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology (2001) 2.63
Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol (2006) 2.53
Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet A (2003) 1.86
Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures. Fam Cancer (2005) 1.58
How families communicate about HNPCC genetic testing: findings from a qualitative study. Am J Med Genet C Semin Med Genet (2003) 1.54
Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med (2001) 1.50
Facilitating family communication about predictive genetic testing: probands' perceptions. J Genet Couns (2005) 1.26
Informing one's family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study. Fam Cancer (2005) 1.15
Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer. Part II: Hereditary nonpolyposis colorectal carcinoma as a model. Cancer (1999) 1.10
Interest in genetic testing among first-degree relatives of colorectal cancer patients. Am J Prev Med (2000) 1.03
Genetic services for familial cancer patients: a follow-up survey of National Cancer Institute Cancer Centers. J Clin Oncol (2005) 0.92
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Statins and the risk of colorectal cancer. N Engl J Med (2005) 6.86
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet (2009) 6.71
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med (2005) 4.27
Statins and cancer prevention. Nat Rev Cancer (2005) 4.12
Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA (2005) 3.99
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res (2006) 3.81
The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med (2010) 3.78
Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst (2013) 3.64
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Small changes in expression affect predisposition to tumorigenesis. Nat Genet (2001) 3.37
ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov (2011) 3.27
Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe (2013) 3.21
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol (2014) 3.07
Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA (2004) 2.99
AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med (2012) 2.87
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology (2009) 2.75
Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA (2006) 2.73
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology (2012) 2.69
An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res (2009) 2.69
The chromosomal instability pathway in colon cancer. Gastroenterology (2010) 2.59
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology (2012) 2.57
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) (2009) 2.46
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol (2010) 2.43
Low rate of microsatellite instability in young patients with adenomas: reassessing the Bethesda guidelines. Am J Gastroenterol (2005) 2.40
Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. J Clin Oncol (2009) 2.38
Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum Genet (2011) 2.35
Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res (2002) 2.33
Risk of pancreatic cancer in families with Lynch syndrome. JAMA (2009) 2.32
Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut (2012) 2.17
NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw (2010) 2.13
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol (2010) 2.10
Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst (2005) 2.10
Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev (2006) 2.04
Exploring utilities and outcomes with infliximab therapy. Clin Gastroenterol Hepatol (2006) 2.04
Tests for gene-environment interaction from case-control data: a novel study of type I error, power and designs. Genet Epidemiol (2008) 2.04
Obesity increases the risks of diverticulitis and diverticular bleeding. Gastroenterology (2008) 2.01
Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol (2012) 1.99
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol (2010) 1.98
Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol (2003) 1.97
Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics (2005) 1.96
The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology (2010) 1.88
BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res (2006) 1.85
Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol (2011) 1.84
Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res (2006) 1.80
A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int J Epidemiol (2006) 1.80
Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). Hum Mutat (2008) 1.76
BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst (2004) 1.76
Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol (2004) 1.76
Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res (2004) 1.76
Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst (2008) 1.71
Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med (2011) 1.70
Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. J Clin Oncol (2010) 1.69
Testing gene-environment interaction in large-scale case-control association studies: possible choices and comparisons. Am J Epidemiol (2011) 1.69
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res (2011) 1.68
Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery (2010) 1.67
The Cables gene on chromosome 18Q regulates colon cancer progression in vivo. Cancer Biol Ther (2005) 1.65
Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) (2012) 1.65
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res (2009) 1.64
AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models. PLoS One (2013) 1.62
Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn (2004) 1.62
Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology (2004) 1.62
Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy. Am J Gastroenterol (2009) 1.62
LKB1--a master tumour suppressor of the small intestine and beyond. Nat Rev Cancer (2002) 1.62
Knowledge of quality performance measures associated with endoscopy among gastroenterology trainees and the impact of a web-based intervention. Gastrointest Endosc (2012) 1.59
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet (2013) 1.56
Risk factors for mortality in lower intestinal bleeding. Clin Gastroenterol Hepatol (2008) 1.55
HIF-1alpha and HIF-2alpha have divergent roles in colon cancer. Int J Cancer (2009) 1.54
Mechanisms of Cables 1 gene inactivation in human ovarian cancer development. Cancer Biol Ther (2007) 1.54
The human visual cortex responds to gene therapy-mediated recovery of retinal function. J Clin Invest (2011) 1.52
The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev (2006) 1.51
Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol (2005) 1.50
Selective Versus Universal Screening for Lynch Syndrome: A Six-Year Clinical Experience. Dig Dis Sci (2014) 1.50
HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol (2010) 1.48
Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw (2014) 1.48